GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » XWELL Inc (NAS:XWEL) » Definitions » Revenue

XWELL (XWEL) Revenue : $30.11 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is XWELL Revenue?

XWELL's revenue for the three months ended in Dec. 2023 was $7.40 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $30.11 Mil. XWELL's Revenue per Share for the three months ended in Dec. 2023 was $1.77. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $7.21.

Warning Sign:

XWELL Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of XWELL was -39.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 24.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was -66.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was -38.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, XWELL's highest 3-Year average Revenue per Share Growth Rate was 1509.10% per year. The lowest was -88.60% per year. And the median was 9.05% per year.


XWELL Revenue Historical Data

The historical data trend for XWELL's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XWELL Revenue Chart

XWELL Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.52 8.39 73.73 55.94 30.11

XWELL Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.56 7.06 8.18 7.47 7.40

Competitive Comparison of XWELL's Revenue

For the Diagnostics & Research subindustry, XWELL's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XWELL's Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, XWELL's Revenue distribution charts can be found below:

* The bar in red indicates where XWELL's Revenue falls into.



XWELL Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $30.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XWELL  (NAS:XWEL) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


XWELL Revenue Related Terms

Thank you for viewing the detailed overview of XWELL's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


XWELL (XWEL) Business Description

Traded in Other Exchanges
N/A
Address
254 West 31st Street, 11th Floor, New York, NY, USA, 10001
XWELL Inc is a health and wellness holding company. It is an airport retailer of spa services through XpresSpa locations, offering travelers premium spa services, including massage, nail, and skincare, as well as spa and travel products. It operates four reportable operating segments: XpresCheck, XpresSpa, Treat, and HyperPointe. XpresSpa is an airport retailer of wellness services and related products. Treat is a travel health and wellness brand that offers in-airport spa and wellness medical services. XpresCheck provides Covid-19 screening and diagnostic testing in partnership with the CDC. HyperPointe is a digital healthcare and data analytics relationship company.
Executives
Suzanne A. Scrabis officer: Chief Financial Officer C/O XWELL, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Scott R Milford officer: Chief Executive Officer C/O TOWN SPORTS INTERNATIONAL, LLC, 5 PENN PLAZA, NEW YORK NY 10001
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Ezra Ernst officer: See Remarks C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Omar Haynes officer: VP Treas & Fi & Interim CFO C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Doug Satzman director, officer: Chief Executive Officer 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
James A. Berry officer: Chief Financial Officer C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Michael Lebowitz director 780 THIRD AVENUE, 12TH FLOOR, C/O XPRESSPA GROUP, INC., NEW YORK NY 10017
Donald E. Stout director 780 THIRD AVENUE, 15TH FLOOR, NEW YORK NY 10017
Mistral Spa Holdings, Llc 10 percent owner C/O MISTRAL CAPITAL MANAGEMENT, LLC, 650 FIFTH AVENUE, 31ST FLOOR, NEW YORK NY 10019
Mistral Capital Management, Llc 10 percent owner 650 FIFTH AVENUE, 31ST FLOOR, NEW YORK NY 10019
Andrew R Heyer other: Former director and 10% owner 501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Calm.com, Inc. 10 percent owner 140 2ND STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Edward Jankowski officer: SVP; CEO of XpresSpa C/O FORM HOLDINGS CORP., 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017